TCGA-BH-A0E1-01A-11R-A056-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 16
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.420
- ESTROGEN_RESPONSE_LATE+0.410
- ESTROGEN_RESPONSE_EARLY+0.400
- G2M_CHECKPOINT+0.400
- OXIDATIVE_PHOSPHORYLATION+0.300
- FATTY_ACID_METABOLISM+0.270
- GLYCOLYSIS+0.270
- HEME_METABOLISM+0.260
- PANCREAS_BETA_CELLS+0.260
- PEROXISOME+0.260
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.490
- INTERFERON_GAMMA_RESPONSE-0.410
- IL6_JAK_STAT3_SIGNALING-0.370
- INFLAMMATORY_RESPONSE-0.310
- INTERFERON_ALPHA_RESPONSE-0.250
- MYC_TARGETS_V2-0.220
- COMPLEMENT-0.190
- TGF_BETA_SIGNALING-0.130
- TNFA_SIGNALING_VIA_NFKB-0.110
- PI3K_AKT_MTOR_SIGNALING-0.060
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A7-A13F-01A-11R-A12P-07 | — | B | 0.805 |
| 2 | BSR_19_0079_A1_S53 | — | B | 0.760 |
| 3 | TCGA-39-5034-01A-01R-1443-07 | — | cohortA3 | 0.745 |
| 4 | TCGA-A2-A04R-01A-41R-A109-07 | — | B | 0.742 |
| 5 | TCGA-D8-A1XJ-01A-11R-A14M-07 | — | C | 0.739 |
| 6 | TCGA-77-7140-01A-41R-2045-07 | — | cohortSQ2 | 0.736 |
| 7 | SRR1313118 | — | B | 0.732 |
| 8 | SRR12202419 | — | — | 0.729 |
| 9 | MNG778 | — | — | 0.729 |
| 10 | TCGA-BH-A0HY-01A-11R-A056-07 | — | C | 0.725 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.420 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.410 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.400 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.270 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.270 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.260 | Temsirolimus | — uncovered |
| PANCREAS_BETA_CELLS | 0.260 | Cobimetinib | — uncovered |
| PEROXISOME | 0.260 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.250 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.240 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.230 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.220 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.220 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.220 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.210 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.210 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.210 | Inavolisib | — uncovered |
| MYOGENESIS | 0.200 | Inavolisib | — uncovered |